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Spinal NR2B Subunit of N-Methyl-D-Aspartate 
Receptors
Che Aishah Nazariah Ismail1,2, Rapeah Suppian1, Che Badariah Abd Aziz2, Khalilah Haris1, Idris Long1
1School of Health Sciences, Universiti Sains Malaysia Health Campus, Kota Bharu, 
2Physiology Department, School of Medical Sciences, Universiti Sains Malaysia Health Campus, Kota Bharu, Malaysia
Background: This study investigated the role of NR2B in a modulated pain process in the painful diabetic neuropathy (PDN) rat 
using various pain stimuli. 
Methods: Thirty-two Sprague-Dawley male rats were randomly allocated into four groups (n=8): control, diabetes mellitus (DM) 
rats and diabetic rats treated with ifenprodil at a lower dose (0.5 µg/day) (I 0.5) or higher dose (1.0 µg/day) (I 1.0). DM was in-
duced by a single injection of streptozotocin at 60 mg/kg on day 0 of experimentation. Diabetic status was assessed on day 3 of the 
experimentation. The responses on both tactile and thermal stimuli were assessed on day 0 (baseline), day 14 (pre-intervention), 
and day 22 (post-intervention). Ifenprodil was given intrathecally for 7 days from day 15 until day 21. On day 23, 5% formalin was 
injected into the rats’ hind paw and the nociceptive responses were recorded for 1 hour. The rats were sacrificed 72 hours post-
formalin injection and an analysis of the spinal NR2B expression was performed.
Results: DM rats showed a significant reduction in pain threshold in response to the tactile and thermal stimuli and higher noci-
ceptive response during the formalin test accompanied by the higher expression of phosphorylated spinal NR2B in both sides of 
the spinal cord. Ifenprodil treatment for both doses showed anti-allodynic and anti-nociceptive effects with lower expression of 
phosphorylated and total spinal NR2B.
Conclusion: We suggest that the pain process in the streptozotocin-induced diabetic rat that has been modulated is associated 
with the higher phosphorylation of the spinal NR2B expression in the development of PDN, which is similar to other models of 
neuropathic rats. 
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INTRODUCTION
Diabetes mellitus (DM) is defined as a metabolic disorder 
characterized by hyperglycemia caused by complete or relative 
insulin depletion [1]. It is known to be related to neurological 
damage in both the peripheral and central nervous system. Di-
abetic neuropathy, which is a long-term complication of diabe-
tes, comprises of several clinical or subclinical presentations. 
One of the clinical presentations of diabetic neuropathy is 
painful diabetic neuropathy (PDN), and it was reported as the 
common source of neuropathic pain. It was reported that 
nearly 30% to 50% of diabetic patients would develop PDN 
which would manifested as spontaneous pain, hyperalgesia, 
and allodynia [2]. 
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The neuropathic pain has been shown to modulate the N-
methyl-D-aspartate (NMDA) receptor subunit composition 
because the mechanism of the neuropathic pain involves the 
occurrence and maintenance of central sensitization [3]. The 
persistent increase in nociceptive transmission via the excit-
atory synaptic transmission by the ionotropic glutamate 
NMDA receptor suggests that it could be a potential target to 
treat PDN. This calcium-permeable receptor needs glutamate, 
glycine and membrane depolarization for the initiation of cen-
tral sensitization [4]. The heteromeric complexes of the NMDA 
receptor comprise three main subunits: NR1, NR2, and NR3 
with eight different (GluN1) subunits, four distinguished NR2 
subunits (NR2A-D and GluN2A-2D) and two NR3 subunits 
(NR3A and NR3B, and GluN3A and GluN3B) [5]. In neuro-
pathic pain, the NMDA receptor plays a prominent role in 
causing a long-lasting increase in the synaptic efficacy such as 
long-term potentiation or central sensitization in the dorsal 
horn. This effect, in turn, leads to the augmentation of the re-
sponse to the sensory inputs [6]. 
Between all the subunits of the NMDA receptor, we focused 
on the role of the NR2B subunit of the NMDA receptor. NR2B 
subunit is reported to be highly implicated in the modulation 
of learning, memory processing, feeding behaviour and most 
importantly, modulating the pain perception [5]. NR2B sub-
unit is known to have relatively restricted dissemination of 
pain transmission and pain regulatory pathways such as in 
forebrain and the superficial dorsal horn of the spinal cord [7]. 
NR2B subunit is also involved in synaptic plasticity and under-
goes phosphorylation at the tyrosine residue [8]. A study con-
ducted by Wei et al. [9] revealed the link between NR2B sub-
unit overexpression in the anterior cingulate and insular corti-
ces of the mice forebrain and the increased responsiveness to 
the hind paw that was injected with inflammatory stimuli. Real 
time polymerase chain reaction analyses demonstrated that 
the upregulation of NR2B subunit mRNA level in a rat’s hind 
paw induced with complete Freund’s adjuvant (CFA) occurred 
as early as 5 hours post-inflammation and persisted for 7 days 
before returning to the baseline level by 2 weeks post-inflam-
mation [10]. Due to the major contribution of the NR2B sub-
unit in the pain transmission, in the present study, we believe 
that it could be a promising target to combat neuropathic pain, 
specifically PDN. It is well accepted that NR2B subunit is in-
volved in transmitting pain signals; however, whether the spi-
nal cord NR2B subunit contributes to the pain transmission in 
PDN remains mostly uncertain. Thus, in the present study, we 
mainly focused on the involvement of NR2B subunit expres-
sion in the development of PDN in the spinal cord of the strep-
tozotocin (STZ)-induced diabetic rats. 
To understand the role of NR2B subunit, we used ifenprodil, 
a selective, atypical non-competitive NMDA receptor antago-
nist which specifically antagonizes NR2B-containing subtype 
of NMDA receptor to examine the roles of NR2B subunit in 
the pathogenesis of PDN. Ifenprodil is effective in specifically 
suppressing NR2B subunit of the NMDA receptor at a 400-
fold lower dose compared to other drugs to inhibit similar re-
ceptors [11]. There were numerous reports that demonstrated 
the anti-nociceptive activity of ifenprodil with a lower side ef-
fect profile in a neuropathic pain rat’s model [12-14]. Thus, in a 
rat model of diabetes induced by STZ, we aimed to understand 
the role of NR2B in the early pathogenesis of PDN using vari-
ous pain stimuli by treating the rats with ifenprodil, an antago-
nist to NR2B subunit. We also aimed to uncover the associa-
tion between the expression of the total NR2B (tNR2B) sub-
unit and its phosphorylation in the spinal dorsal horn with the 
tactile allodynia, thermal hyperalgesia and formalin-induced 
nociceptive responses in the STZ-induced diabetic rat’s model.
METHODS
Animals
The study was performed on 32 Sprague-Dawley male rats 
weighing 200 to 230 g (8 to 10 weeks old). They were housed 
individually in an air-conditioned room (20°C) and main-
tained on a 12-hour light/dark cycle (7:00 AM to 7:00 PM). All 
the animals were fed a standard diet and had free access to wa-
ter. The experimental procedures conducted in the present 
study were in compliance with the Animal Ethics Approval 
(USM/Animal Ethics Approval/2014 [91] [560]). The percent-
age of the changes in the body weight gain of the rats through-
out the study period was recorded according to the formula 
below:
% Change of body weight gain 
= Body weight on day 26 – body weight on day 0
 × 100%
  Body weight on day 0
Streptozotocin-induced diabetes in rats
All the rats fasted for at least 14 hours before the induction of 
diabetes. DM was induced by a single intraperitoneal injection 
of STZ (Sigma-Aldrich, Darmstadt, Germany) at a dose of 60 
mg/kg body weight, freshly dissolved in a citrate buffer (pH 
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4.5) as a vehicle. Meanwhile, the control rats were injected in-
traperitoneally with citrate buffer respectively. A 10% sucrose 
solution was given to the rats for 1 day to avoid the develop-
ment of severe hypoglycaemia in rats that could be lethal. Dia-
betes was confirmed 3 days after the STZ injection by obtain-
ing the blood via pin-prick at the tip of the tail, whilst the con-
trol group remains non-diabetic. The blood glucose level was 
measured before the induction of STZ (day 0), after the induc-
tion of STZ (day 3), on the pre-intervention day (day 14), and 
post-intervention day (day 22) using a strip-operated glucom-
eter (Accu-chek Performa; Roche Diagnostics, Paris, France). 
The animals with the final blood glucose level ≥270 mg/dL 
were considered as diabetic. 
Pain threshold assessment 
Tactile allodynia by automatic von Frey apparatus
Tactile allodynia was measured in all the rats using an auto-
matic von Frey apparatus (Bioseb, Pinellas Park, FL, USA). The 
rats were placed on a wire mesh floor in a quiet room and al-
lowed to acclimatize for a minimum of 15 minutes before be-
ginning the test. A semi-flexible filament weighing 0.099 g was 
applied to the mid-plantar region of the hind paw. The pres-
sure was gradually increased until either a clear retraction, 
licking or jumping was observed. The force applied to the fila-
ment which evoked a hind paw withdrawal represented a 
maximal threshold and expressed in grams. The stimulation 
was conducted three times, and the average measurement was 
calculated. The stimulation using the filament was applied per-
pendicularly to both the right and left hind paws, separated by 
10 minutes of interval from the previous tactile stimulation of 
the paw [15]. On day 14 (pre-intervention day), the rats were 
considered hyperalgesic when the reduction in the nociceptive 
pain thresholds by the von Frey test was more than 15% of the 
value obtained before the STZ injection (day 0) [16]. Mean-
while, the rats with the reduction in the nociceptive pain 
threshold by the von Frey test of less than 15% of the value ob-
tained before the STZ injection were determined as non-PDN 
rats. The non-PDN rats showed hypoalgesic/analgesic behav-
iour at the early course of diabetic when subjected to various 
pain stimulation compared to the normal and DM rats which 
were accompanied with a reduced expression of total and 
phosphorylated NR2B subunit NMDA receptor compared to 
the control and DM groups. We decided to exclude the non-
PDN rats’ results because we were unsure about the possible 
mechanism for hypoalgesic/analgesic behaviour effects and 
planned to do further investigation to elucidate the mecha-
nism of different phenotypes in the diabetic-induced rats in 
our study.
Thermal hyperalgesia by hot-plate test
Thermal hyperalgesia was measured for the paw withdrawal 
latency to thermal stimuli using a hot-plate test (Bioseb). The 
temperature was constantly set at 52.5°C. The latency to re-
spond with either a hind paw lick, hind paw flick or jump from 
the onset of the heat stimulation was recorded [17]. The test 
was terminated if the animals did not respond within 30 sec-
onds and each animal was tested only once to avoid adapta-
tion.
Experimental grouping and intrathecal drug 
administration
Adult rats were randomly assigned to four experimental 
groups (eight rats per group): (1) control, treated with vehicle 
(saline 0.9%); (2) DM control rats treated with vehicle; (3) DM 
rats treated with ifenprodil either at a lower dose (0.5 µg/day) 
(I 0.5); or (4) at a higher dose (1.0 µg/day) (I 1.0). The dose of 
20 µL of either normal saline 0.9% or ifenprodil (0.5 or 1.0 µg/
day) was given to the rats, intrathecally every day for 7 days 
starting from day 15 to 22 post STZ injection. 
The direct intrathecal administration of the treatment was 
performed following a method by Lu and Schmidtko [18]. The 
rats were initially anaesthetized with isoflurane using an anaes-
thesia machine. During the anaesthetic state, the rats were re-
moved and shaved at the back of the body. The area between 
L5 and L6 spinous processes were used as the skin puncture 
site, in which this area corresponds to the cauda equina. The 
vertical puncture of a 30 G needle connected to 1 mL syringe 
to the dura mater was reliably confirmed by either a reflexive 
flick of the tail or the formation of an ‘S’ shape by the tail. The 
treatment was slowly injected into the intervertebral space 
within 2 seconds. Finally, the rats were observed for 2 minutes 
after the injection to ensure there was no injury or any motor 
impairment in the rats.
Formalin test
The rat received an intraplantar injection of 50 µL of 5% for-
malin solution into the dorsal surface of the right hind paw 
and was immediately transferred to a Perspex testing chamber 
(26×20×20 cm). A mirror was placed beneath the floor direct-
ing the base of the chamber at a 45° angle to allow an unob-
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structed view of the paw. The nociceptive response was record-
ed for 60 minutes using a video camera. The recorded response 
was assessed by two persons blinded to any treatment based on 
the pain score from 0 to 3, as follows: 0, the rats feel no pain at 
all (i.e., foot flat on the floor with all toes splayed); 1, the inject-
ed paw has little or no weight on it, with no toes splaying, indi-
cating mild pain; 2, the injected paw is elevated and the heel is 
not in contact with any surface, indicating moderate pain; 3, 
the injected paw is licked, bitten or shaken, an indication of se-
vere pain felt. 
The nociceptive responses were then tabulated every minute 
and averaged at 5-minute intervals [19]. The nociceptive re-
sponses were divided into three phases comprising of phase 1 
(mean score from minute 0 to 10), early phase 2 (mean score 
from minute 15 to 35), and late phase 2 (mean score from min-
ute 40 to 60).
Immunohistochemistry for total NR2B subunit and a 
phosphorylated NR2B subunit of the NMDA receptors 
positive neurons expressions
Seventy-two hours after the formalin test was conducted, the 
rats were deeply anaesthetized with sodium pentobarbitone 
(Alfasan, Woerden, Netherlands) intraperitoneally. In our un-
published work, the activated microglia were shown to be 
clearly expressed and localized to the portion of lamina I-IV in 
the spinal cord at 3 days after the formalin injection. This find-
ing has also been supported by Fu et al. [20]. It is the reason of 
sacrificing the rats at 3 days after formalin injection. Thoracot-
omy was carried out to expose the heart. The left ventricle of 
the rat’s heart was inserted with an 18 G needle (branula) and a 
snip was made to the right atrium for an outlet. Perfusion was 
conducted by means of the gravity method using phosphate 
buffered saline (PBS) and post-fixed with 500 mL of fresh, cold 
4% paraformaldehyde in 0.1 M phosphate buffer (PB) (pH 
7.4). The lumbar enlargement region of the spinal cord (L4-L5) 
(which innervates the hind paw) was removed. Following an 
overnight cryoprotection in 20% sucrose in PB 0.1 M, L4 and 
L5 segments were sectioned (40 µm thickness) using a cryostat 
and every third section was collected as a free-floating section 
in PBS. The sections were rinsed with Tris-buffered saline 
(TBS) twice for 5 minutes each and incubated for 48 hours at 
4°C with either primary rabbit polyclonal for NR2B (1:500; 
Thermo Scientific, Waltham, MA, USA) or phosphorylated 
NR2B (pTyr-1336, 1:400; Thermo Scientific) antibodies dilut-
ed in TBS containing blocking solutions of 2% normal goat se-
rum and 0.2% Triton X-100. The sections were then washed in 
Tris-triton and incubated with the biotinylated secondary anti-
body (goat anti-rabbit anti-serum, Rabbit ABC Staining Sys-
tem; Thermo Scientific) with a dilution of 1:200 for 1 hour at 
room temperature (RT). After additional rinses in TBS/Triton, 
all the sections were incubated with avidin-biotin-HRP (dilut-
ed 1:50 in TBS; Thermo Scientific) for 1 hour at RT. All the sec-
tions were again rinsed with TBS/Triton before being visual-
ized with 3, 3´-diaminobenzidine (0.02% in TBS, 0.2% hydro-
gen peroxide; Thermo Scientific) as a chromogen. The immu-
nostained sections were air-dried overnight, dehydrated with 
absolute ethanol, cleared, mounted onto gelatin-subbed slides 
and cover-slipped with DPX mounting solution (BDH Labora-
tory, Poole, UK). Six random sections were captured using an 
image analyzer (Leica MPS 60; Leica, Tokyo, Japan) under 
100× magnifications. The total number of protein expression 
was counted manually from laminae I to VI and the average of 
six sections were taken from each rat from the ipsilateral and 
contralateral sides.
Western blot analysis
The tNR2B subunit and the phosphorylated NR2B subunit of 
the NMDA receptors level in the spinal cord was determined 
by the Western blot analysis. Seventy-two hours post-formalin 
injection, the rats were sacrificed by decapitation using a guil-
lotine after being deeply anaesthetized with an overdose injec-
tion of sodium pentobarbitone intraperitoneally. The lumbar 
enlargement region of the spinal cord was dissected out from 
the rats without a fixation process and separated into the ipsi-
lateral and contralateral sides by a cut at the midline of the spi-
nal cord. Immediately after the removal, the tissue was deep-
frozen in liquid nitrogen and kept at –80°C until further assay. 
The protein was extracted from the spinal cord tissue using ice-
cold RIPA buffer (Thermofisher Scientific) that was freshly 
mixed with concentrated Halt Protease and Phosphatase cock-
tail kit (Pierce, Rockford, lL, USA) in a volume of 10 µL/mL 
per reagent. The protein concentration of the extracted sam-
ples was determined by the bicinchoninic acid (BCA) protein 
assay kit (Thermofisher Scientific). The protein samples con-
taining 50 µg of the total protein (after the optimization) was 
denatured and subjected to sodium dodecyl sulfate polyacryl-
amide gel electrophoresis (SDS-PAGE) using 15% resolving 
gel. The proteins from the gel were transferred to a nitrocellu-
lose membrane (Bio-Rad, Hercules, CA, USA) with a semi-dry 
protein transfer apparatus set at 13 V for 2 hours. The nitrocel-
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lulose membrane was incubated in blocking the solution at ei-
ther 5% bovine serum albumin in TBS (for NR2B subunit pro-
tein) or 5% skimmed milk in TBS (for phosphorylated-NR2B 
subunit) for 1 hour at RT. Following that, the membrane was 
washed three times for 10 minutes each in Tris-buffered saline-
Tween 20 (TBST). The membrane was then incubated with ei-
ther rabbit polyclonal NR2B subunit antibody (1:1,000 dilution 
in TBST), rabbit polyclonal phosphorylated NR2B subunit 
(Tyr1336, 1:500 dilution in TBST), or mouse monoclonal 
β-actin antibody (dilution 1:2,000 in TBST) overnight at 4°C. 
The membrane was then incubated with HRP-conjugated goat 
anti-rabbit antibody (dilution 1:5,000 in TBST for NR2B sub-
unit and phosphorylated-NR2B subunit proteins) or mouse 
secondary antibody (dilution 1:5,000 in TBST for β-actin pro-
tein) for 1 hour at RT. Between the incubations, the membrane 
was washed three times for 10 minutes each and the blot was 
examined using Clarity Western ECL Substrate (Thermofisher 
Scientific). The image was taken by an image analyzer Fusion 
FX Chemiluminescence Imaging (Analis, Namur, Belgium) 
apparatus. The integrated density values (IDV) of the NR2B 
subunit, the phosphorylated NR2B subunit of NMDA recep-
tors and β-actin proteins were measured using FUSION-CAP 
software (Analis) in the image analyzer. The mean relative in-
tensity of fold change was measured using the formula below:
Mean relative Intensity=(IDV NR2B subunit or phosphory-
lated-NR2B subunit–IDV endogenous control)target group–(IDV 
NR2B subunit or phosphorylated-NR2B subunit–IDV endog-
enous control)calibrator group.
Statistical analysis
The data was analyzed using SPSS software version 22 (IBM 
Co., Armonk, NY, USA). The percentage of change in body 
weight gain, the nociceptive response phases using the forma-
lin test (phase 1, early phase 2, and late phase 2), the total num-
bers of NR2B subunit and phosphorylated NR2B subunit of 
NMDA receptors positive neurons, mean relatives NR2B sub-
unit and phosphorylated NR2B subunit protein levels were an-
alyzed using a one-way analysis of variance (ANOVA) with the 
post hoc least-significant differences (LSD) or Dunnett’s T3 
tests. Meanwhile, the blood glucose level, tactile allodynia, and 
thermal hyperalgesia were analyzed using one-way repeated 
measures ANOVA with Greenhouse-Geisser correction fol-
lowed by a post hoc LSD test. The results were expressed as a 
mean±standard error of the mean (SEM), standard deviation 
(SD), and the level of significance was determined at P<0.05.
RESULTS
Changes in the percentage of body weight gain and blood 
glucose level
The DM rats show significant weight loss throughout the study 
compared to the control group (P<0.001) (Table 1). Although 
the ifenprodil-treated groups exhibit a marked reduction in the 
percentage of body weight gain compared to the control group 
(P<0.001), they show a prominent increase in the percentage 
of body weight gain compared to the DM group especially if a 
higher dose is used (I 1.0) (P<0.001), indicating the ifenprodil 
treatment may reverse the body weight loss in the PDN rats. 
Furthermore, all the DM rats show a significant increase in 
blood glucose level compared to the control rats and they are 
maintained as diabetics from day 3 until post-intervention 
(day 22) (P<0.001). The result show that the group treated 
with ifenprodil at both doses significantly reduce the blood 
sugar level after 7 days of treatment compared to the DM 
group (P<0.001) (Table 1).
Tactile allodynia by automatic von Frey apparatus.
Generally, all the rats with diabetic exhibit a strong tactile allo-
Table 1. Percentage of change of body weight and blood glucose level between the groups (n=8)
Group % Body weight gain, g
Blood glucose level, mg/dL
Baseline 
(day 0) Day 3
Pre-intervention 
(day 14)
Post-intervention 
(day 22)
Control 68.34±5.15 4.52±0.42 120.00±18.55 109.09±12.73 107.27±18.00
DM –17.7±3.4a 4.43±0.52 568.64±75.27a 571.64±62.00a 590.91±45.09a
(I 0.5) 4.15±3.8a,b,c 4.76±0.61 520.00±70.91b 543.64±71.82b 563.09±68.18b
(I 1.0) 36.6±9.6a,d 4.99±0.61 465.45±103.64a,d 529.09±61.82a,d 510.91±47.27a,d
Values are presented as mean±standard deviation.
aP<0.001 compared to control group, bP<0.05 compared to DM group, cP<0.05 compared to (I 1.0), dP<0.001 compared to DM group.
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dynia effect at 2 weeks after the diabetic induction. Specifically, 
there is a statistically significant difference in the pain thresh-
old on the left hind paw of the rats (P<0.001) between the 
groups. The post hoc LSD test reveals that the DM group has 
significantly reduced noxious withdrawal threshold on day 14 
(pre-treatment) and it is maintained reduced on day 22 (post-
treatment) compared to the control group (P<0.001). Ifenpro-
dil at both doses significantly reverses the allodynia develop-
ment by increasing the noxious withdrawal threshold in the 
DM rats after the treatment. No significant difference is seen in 
the increase of noxious withdrawal threshold in the ifenprodil-
treated groups between the lower and higher doses used (Fig. 
1A).
There is also a statistically significant difference in the tactile 
allodynia effect on the right hind paw of the rats between the 
groups (P<0.001). The post hoc LSD test reveals that the DM 
group is shown to be strongly allodynic compared to the con-
trol group (P<0.001) throughout the study period. The re-
duced noxious withdrawal threshold at the right hind paw of 
the DM rats is shown to be corrected by both the lower and 
higher doses of ifenprodil after the treatment periods (Fig. 1B).
Thermal hyperalgesia by hot-plate test
The DM group does not produce and thermal hyperalgesia 
demonstrated by the insignificant difference in the thermal 
withdrawal threshold compared to the control group. The 
treatment by ifenprodil at both doses do not alter the thermal 
withdrawal threshold as evaluated on day 22 (Fig. 2).
Nociceptive response by formalin test
The nociceptive response using the formalin test is divided 
into three phases: phase 1 (0 to 10 minutes), early phase 2 (15 
to 35 minutes), and late phase 2 (40 to 60 minutes). There is a 
statistically significant difference between the groups during 
phase 1, early phase 2, and late phase 2 for nociceptive behav-
iour score (P<0.05). The post hoc LSD test reveals that the no-
ciceptive responses in the DM rats regardless of treatment are 
significantly hyperalgesic during the phase 1 (P<0.05) and 
early phase 2 (P<0.05) but not during late phase 2 compared 
to the control group. The DM rats treated with ifenprodil at 
both doses have been shown to significantly reduce the noci-
ceptive behaviour score in all phases compared to DM group 
(P<0.05) (Fig. 3).
Total numbers of total NR2B subunit positive neurons 
The positive and negative controls for the tNR2B subunit of 
NMDA receptors are demonstrated in Fig. 4A and B. There is a 
significant effect on the total number of NR2B subunit positive 
neurons between the groups in the ipsilateral (P<0.001) and 
contralateral sides (P<0.001) of the spinal cord of rats. The to-
tal numbers of NR2B subunit positive neurons are found to be 
significantly increased in the DM group compared to the con-
trol group in both ipsilateral and contralateral sides. Mean-
while, the intrathecal administration of ifenprodil at both doses 
demonstrates a marked attenuation in the tNR2B total expres-
sion at both the ipsilateral and contralateral sides of rat’s spinal 
cord compared to the DM and control groups (Table 2, Fig. 4). 
Fig. 1. (A) Tactile allodynia represented by von Frey test between the groups on day 0 (baseline), day 14 (pre-intervention), and 
day 22 (post-intervention) on the left hind paw (n=8). (B) Tactile allodynia represented by von Frey test between the groups on 
day 0 (baseline), day 14 (pre-intervention), and day 22 (post-intervention) on the right hind paw (n=8). DM, diabetes mellitus. 
aP<0.001 significant compared to control group, bP<0.001 significant compared to DM group, cP<0.05 significant compared to 
DM group.
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Fig. 2. Duration of paw licking or jumping by hot-plate test between the groups (n=8). Values are expressed as mean±standard 
error of the mean. No significant differences were detected between groups. DM, diabetes mellitus.
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Fig. 3. Chemical hyperalgesia represented by nociceptive response between the groups (mean±standard error of the mean) 
(n=8). DM, diabetes mellitus. aP<0.05 significant compared to control group, bP<0.05 compared to DM group, cP<0.001 signifi-
cant compared to DM and control groups.
2.5
2.0
1.5
1.0
0.5
0
N
oc
ice
pt
iv
e b
eh
av
io
ur
 sc
or
e
Control
 Phase 1  Early phase 2  Late phase 2
DM (I 0.5) (I 1.0)
a
a
b
b
b
b
b
c
Table 2. Total number of tNR2B and pNR2B positive neurons on ipsilateral and contralateral sides for all groups 3 days after for-
malin injection (n=8)
Group Control DM (I 0.5) (I 1.0)
tNR2B
   Ipsilateral 1,151±152.5 1,849±144a 846±243b,c 402±116d,e 
   Contralateral 1,032±190.1 1,622±274.1a 708±180.5b,c 339±93.2d,f
pNR2B
   Ipsilateral 1,401±177.9 1,676±236.4b 560±112.4d 436±87.5d
   Contralateral 1,255±236.4 1,375±251.4b 464±115.9d 399±90.9d
Values are presented as mean±standard deviation.
tNR2B, total NR2B subunit; pNR2B, phosphorylated NR2B subunit; DM, diabetes mellitus.
aP<0.001 compared to control group, bP<0.05 compared to control group, cP<0.001 compared to DM group, dP<0.001 compared to DM and 
control groups, eP<0.001 compared to (I 0.5) group, fP<0.05 compared to (I 0.5) group. 
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Fig. 4. Immunohistochemistry image showed the total expres-
sion of total NR2B subunit positive neurons (tNR2B) in lami-
nae I-II on ipsilateral (i) and contralateral (c) sides of rat spinal 
cord at 40× magnification. (A) The positive control for NR2B 
subunit in the rat’s brain (thalamus) whilst. (B) The negative 
control in the rat’s spinal cord region. (C) Control group. (D) 
Diabetes mellitus group. (E) (I 0.5) group. (F) (I 1.0) group. Ar-
rows indicate the dark staining of tNR2B subunit positive neu-
ron expression.
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Fig. 5. Immunohistochemistry image showed the expression 
of phosphorylated-NR2B subunit positive neurons in laminae 
I-II on ipsilateral (i) and contralateral (c) sides of rat spinal 
cord at 40× magnification. (A) The positive control for phos-
phorylated-NR2B subunit in the rat’s brain (thalamic region) 
whilst. (B) The negative control in the rat’s spinal cord region. 
(C) Control group. (D) Diabetes mellitus group. (E) (I 0.5) 
group. (F) (I 1.0) group. Arrows indicate the dark staining of 
phosphorylated-NR2B subunit positive neurons.
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Total number of phosphorylated NR2B subunit positive 
neurons
The positive and negative controls for the tNR2B subunit of 
NMDA receptors are demonstrated in Fig. 5B and C. There is a 
significant difference in the total number of the phosphorylat-
ed NR2B subunit of NMDA receptors between the groups on 
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the ipsilateral side (P<0.001) and contralateral side (P<0.001) 
of the rat’s spinal cord. The post hoc LSD test reveals that the 
total number of the phosphorylated NR2B subunit positive 
neurons in the ipsilateral and contralateral sides of the spinal 
cord has significantly increased in the DM group compared to 
the control group (P<0.05). The intrathecal administration of 
ifenprodil at both the lower (0.5 µg/day) and higher (1.0 µg/
day) doses has significantly attenuate the total numbers of 
phosphorylated NR2B subunit positive neurons compared to 
the DM and control groups at both the ipsilateral and contra-
lateral sides of the spinal cord. No significant difference is de-
tected in the total number of the phosphorylated NR2B sub-
unit of NMDA receptors between the given doses of ifenprodil 
(Table 2, Fig. 5).
Mean relative total NR2B subunit protein level
The mean relative total the NR2B subunit protein level at the ip-
silateral and contralateral sides of the spinal cord has signifi-
cantly increased in the DM group compared to the control 
group (P<0.05). In contrast, the intrathecal administration of 
ifenprodil at a lower (I 0.5) and higher (I 1.0) doses significantly 
decrease the mean relative of the tNR2B subunit protein level 
compared to the DM group ipsilaterally and contralaterally 
(P<0.001). No effect is seen in the mean relative level of tNR2B 
subunit protein level between (I 0.5) and (I 1.0) groups at the ip-
silateral and contralateral sides of the spinal cord (Figs. 6 and 7).
Mean relative phosphorylated NR2B subunit protein level
The mean relative level of the phosphorylated NR2B subunit of 
NMDA receptors is significantly increased in the DM group 
compared to the control group (P<0.05). The administration 
A
B
Fig. 6. (A) A representative example of Western blot results for 
total NR2B subunit on the ipsilateral side between all groups 
with quantification analysis of the integrated density value. (B) 
Columns represent the mean relative total NR2B subunit pro-
tein level±standard error of the mean for eight separate exper-
iments. The mean relative total NR2B subunit protein level 
(fold change) represents comparative levels of the total NR2B 
subunit protein in the experimental groups (diabetes mellitus 
[DM], DM group treated with ifenprodil at lower dose, I 0.5 
and DM group treated with ifenprodil at higher dose, I 1.0) 
over the calibrator group (control group) after normalization 
by its loading control (housekeeping protein, β-actin protein) 
(n=8 for each group). aP<0.05 compared to control group, 
bP<0.001 compared to DM group. 
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Fig. 7. (A) A representative example of Western blot results for 
total NR2B subunit on the contralateral side between all 
groups with quantification analysis of the integrated density 
value. (B) Columns represent the mean relative total NR2B 
subunit protein level±standard error of the mean for eight 
separate experiments. The mean relative total NR2B subunit 
protein level (fold change) represents comparative levels of the 
total NR2B subunit protein in the experimental groups (diabe-
tes mellitus [DM], DM group treated with ifenprodil at lower 
dose, I 0.5 and DM group treated with ifenprodil at higher 
dose, I 1.0) over the calibrator group (control group) after nor-
malization by its loading control (housekeeping protein, 
β-actin protein) (n=8 for each group). aP<0.05 compared to 
control group, bP<0.001 compared to DM group.
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of ifenprodil at both lower and higher doses on DM rats signif-
icantly inhibited the phosphorylation of the NR2B subunit of 
the NMDA receptors ipsilaterally and contralaterally (P< 
0.001). No significant difference is detected in the inhibition of 
phosphorylation of the NR2B subunit of the NMDA receptors 
between the doses of ifenprodil given (Figs. 8 and 9).
DISCUSSION
As demonstrated in the present study, the rats in the DM group 
exhibited a marked reduction in the percentage of body weight 
gain, demonstrated higher tactile allodynia and hyperalgesia 
effects at 2 weeks after the induction of diabetes and main-
tained as hyperglycemic throughout the experimental period 
as determined by the blood glucose level taken on day 0, 3, 14, 
and 22. This effect was accompanied by a higher expression of 
the total and the phosphorylated NR2B subunit of the NMDA 
receptors as demonstrated by both the immunohistochemistry 
and Western blot analyses. The treatment of ifenprodil howev-
er reversed these effects.
The previous reports demonstrated that the administration 
of ifenprodil at the lateral hypothalamic area in the brain 
would suppress the feeding satiety in the animals and this leads 
to the reduction in body weight. This suppression suggests that 
the feeding-related lateral hypothalamic area may contain the 
NR2A and/or NR2B subunits NMDA receptor and blockade 
A
B
Fig. 8. (A) A representative example of Western blot results for 
phosphorylated NR2B (pNR2B) subunit on the ipsilateral side 
between all groups with quantification analysis of the integrat-
ed density value. (B) Columns represent the mean relative 
pNR2B subunit protein level±standard error of the mean for 
eight separate experiments. The mean relative pNR2B subunit 
protein level (fold change) represents comparative levels of the 
pNR2B subunit protein in the experimental groups (diabetes 
mellitus [DM], DM group treated with ifenprodil at a lower 
dose, I 0.5 and painful diabetic neuropathy group treated with 
ifenprodil at a higher dose, I 1.0) over the calibrator group 
(control group) after normalization by its loading control 
(housekeeping protein, β-actin protein) (n=8 for each group). 
aP<0.001 compared to control group, bP<0.05 compared to 
control group, cP<0.001 compared to DM group, dP<0.001 
compared to DM group and control groups.
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Fig. 9. (A) A representative example of Western blot results for 
phosphorylated NR2B (pNR2B) subunit on the contralateral 
side between all groups with quantification analysis of the inte-
grated density value. (B) Columns represent the mean relative 
pNR2B subunit protein level±standard error of the mean for 
eight separate experiments. The mean relative pNR2B subunit 
protein level (fold change) represents comparative levels of the 
pNR2B subunit protein in the experimental groups (diabetes 
mellitus [DM], DM group treated with Ifenprodil at a lower 
dose, I 0.5 and DM group treated with Ifenprodil at a higher 
dose, I 1.0) over the calibrator group (control group) after nor-
malization by its loading control (housekeeping protein, 
β-actin protein) (n=8 for each group). aP<0.05 compared to 
control group, bP<0.001 significant compared to DM and con-
trol groups.
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of this subunit receptor will affect feeding satiety and food in-
take [21,22]. However, another previous study that adminis-
tered ifenprodil at the hindbrain area demonstrated that ifen-
prodil did not participate in increased food intake effect which 
was not similar to the MK 801 action in this area [23]. In this 
study, the DM rats treated with ifenprodil intrathecal especially 
at a higher dose (I 1.0) exhibited a marked higher percentage 
of body weight gain compared to the untreated DM rats. The 
rats used in the present study were diabetic, and the treatment 
was done by intrathecal in the spinal cord area. Therefore, it is 
unclear how the ifenprodil acts on the feeding satiety and body 
weight reduction effects, since all these control areas are local-
ized in the brain. It could be possible that the diabetic and ifen-
prodil treatment may influence another pathway(s) that may 
regulate the feeding behaviour or other possible pathways 
leading to body weight gain in these group rats, which needed 
to be discovered in future. 
The intrathecal delivery of the ifenprodil treatment is also 
shown to suppress tactile allodynia in both the hind paws and 
formalin-induced nociceptive responses. A similar finding was 
reported by Zhang et al. [24] in the chronic dorsal root ganglia 
compression rat model. The sprouting of A-fibres in the spinal 
cord which is responsible for proprioception and the somatic 
motor is one of the central mechanisms responsible for the 
generation of tactile allodynia. When the peripheral nerve is 
damaged, it induces the sprouting of Aβ-fibre terminals from 
the deeper laminae to the superficial laminae of the spinal 
cord. Since the NR2B subunit of the NMDA receptors is main-
ly localized in the superficial laminae, it may explain the pref-
erential of this subunit for mediating the tactile allodynia [25]. 
This may also explain the reduction of the allodynic state in the 
DM rats treated with intrathecal ifenprodil on day 22 (post-in-
tervention) on both the right and left hind paws in this study. 
The induction of A-fibre sprouting after the nerve damage may 
also describe the allodynic effect in the DM rats on day 14 until 
day 22 in both of their hind paws. Both developments of ther-
mal hyperalgesia and tactile allodynia involve supraspinal sites, 
possibly dorsal column nuclei [26]. Ifenprodil possibly sup-
presses the pain transmission in the spinal cord by attenuating 
the descending excitatory influences. It is also agreed by Chizh 
et al. [12] that ifenprodil might block the supraspinal site, or if 
such descending excitatory processes includes the spinal 
NMDA receptors, ifenprodil could specifically reduce the de-
scending facilitation by inhibiting the NR2B-containing recep-
tors in the spinal cord. 
In this study, although the DM rats exhibited allodynia, they 
did not develop thermal hyperalgesia as assessed by the hot-
plate test. The results were similarly reported by previous stud-
ies [27,28] although it may also be found to be inconsistent 
with most of the reported studies [29,30]. Although it is in-
triguing, the peculiarity of the STZ-induced diabetic rats that 
develop allodynia but not thermal hyperalgesia is actually not 
unique. As an example, the development of allodynia and hy-
peralgesia but not followed by thermal hyperalgesia had been 
reported in the animal model of the sciatic nerve cryoneuroli-
sis (SCN) [31]. This means that diabetic and SCN models of 
neuropathic pain are distinguishable from the other models of 
neuropathic pain such as chronic constriction injury, partial 
nerve ligation, and spinal nerve root ligation which produce 
both thermal hyperalgesia and allodynia at the ipsilateral side 
to the lesion. It can be suggested that the different types of pe-
ripheral nerve are selectively damaged in these models [27]. 
Moreover, the paw withdrawal responses to the noxious ther-
mal signals are related to the supraspinal sensory processing 
[32] and it is also well-known that the thermal nociceptive ac-
tivation does not stimulate as much mechanoreceptor signals 
like the mechanical stimulation do [33]. Thus, it is probable 
that the diminution of the low threshold mechanoreceptors or 
demyelination has occurred in the diabetic rats leading to the 
reduced mechanoreceptors. Plus, some inhibitory controls are 
possibly lost and destroyed, thus exaggerating these effects 
[27]. Furthermore, it has been reported that the content of 
substance P which participates in the development of nerve-
injury related thermal hyperalgesia was reduced in the sciatic 
nerve [34] and spinal cord of the diabetic rats [27]. Hence, this 
could explain the reason for the non-development of thermal 
hyperalgesia in the DM rats in this study. 
The formalin test has two phases of pain (phase 1 and 2) in 
which phase 1 comprises of direct chemical stimulation of the 
pain receptors and local inflammatory processes, and phase 2 
is caused by the neural mechanisms in the spinal cord level 
[35]. One to five percent of the formalin injection on the rat’s 
hind paw produces long-lasting sensitization, as demonstrated 
by Fu et al. [36]. In general, the untreated DM rats in the pres-
ent study have shown to robustly increase their nociceptive re-
sponses, and the responses are greater than those in the control 
rats. This indicates that hyperalgesia effect, as similarly report-
ed by Courteix et al. [37], in the diabetic-induced PDN rat 
model. The DM rats showed a greater hyperalgesic state than 
the control rats during phase 1. During the early and late stages 
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of phase 2, the untreated DM rats also exhibited a higher noci-
ceptive response compared to the control rats indicating they 
were in severe pain and it could be developed into PDN.
We expected that this effect could be due to the higher ex-
pression of the tNR2B subunit of the NMDA receptors and its 
phosphorylation in the spinal dorsal horn, as demonstrated by 
the immunohistochemistry and Western blot analyses, which 
may explain the persistent activation of the central sensitiza-
tion after being injected with 5% formalin. This could be ex-
plained by a previous report of the phosphorylated NR2B sub-
unit of the NMDA receptors in the spinal cord following an in-
flamed hind paw induced by CFA or mustard oil [8]. Guo et al. 
[8] agreed that the development of the hind paw inflammation 
and hyperalgesia are highly related to a rapid and prolonged 
increase in the phosphorylation of NR2B subunit of the 
NMDA receptors in the spinal cord. 
The present study also shows that the ifenprodil treatment at 
both doses (I 0.5 and I 1.0) can reduce the nociceptive respons-
es during both phase 1 and 2 of the formalin test. Ifenprodil 
may inhibit the NR2B subunits of the NMDA receptors ex-
pressed on the neurons of small-diameter primary afferents 
[38] as well as the spinal dorsal horn. The previous studies have 
also agreed that NMDA receptors antagonists only had a mi-
nor effect on the pain-producing nociceptive response seen 
during phase 1, but potently eliminate the phase 2’s reactions 
after the formalin-induced inflammatory pain [36]. A study by 
Tan et al. [39] discovered that the NMDA-2B knock-down rats 
were shown to attenuate to the formalin-induced pain behav-
iour after the intrathecal administration of the small interfer-
ing RNAs. Besides that, Zhang et al. [24] reported that the 
NR2B subunit of the NMDA receptors showed a distribution 
related to small diameter fibres in lamina I and II, suggesting 
the presence of primary afferent origin and post-synaptically 
on the dorsal horn neurons. Therefore, in this study, the atten-
uation of allodynia and formalin-induced inflammatory pain 
behaviour of the formalin test using ifenprodil is highly be-
lieved to be contributed by the suppression of the NR2B sub-
unit and its tyrosine phosphorylation. Taken together, it may 
prove that the activation of the spinal cord NR2B is involved in 
the development of PDN although its distribution is quite lim-
ited in the superficial laminae of the rat’s spinal cord [6]. 
In the present study, the higher or lower expressions and 
mean relative of the total and phosphorylated NR2B subunit of 
NMDA receptors were prominent not only at the ipsilateral 
side but also at the contralateral side of the spinal cord of the 
rats. This bilateral expression of these proteins is suggested due 
to the ‘mirror’ pain effect. Aloisi et al. [40] believed that when 
5% of the formalin solution was given to one of the rat’s hind 
paw (ipsilateral side) at the intraplantar region. Therefore, the 
mirror pain effect was detected on the other non-injected hind 
paw (contralateral side). It is believed that this mirror pain ef-
fect is derived from an altered spinal processing of the incom-
ing sensory inputs, specifically mediated by the NMDA or 
neurokinin receptors which are assumed to play a major func-
tion in the persistent nociceptive mechanisms after the forma-
lin injection.
In conclusion, we suggest that the higher allodynic and hy-
peralgesic effects as shown in the STZ-induced diabetic rats 
could be the indicator that the rats develop into the PDN. The 
development of the PDN could directly involve the modula-
tion of the pain process by upregulating the phosphorylation 
of the NR2B subunit of the NMDA receptors in the superficial 
dorsal horn of the rats’ spinal cord in this study, which is simi-
lar with the mechanism of other neuropathic pain rat models. 
There are other possible factors that contribute to the develop-
ment of PDN in STZ-induced diabetic rats such as the role of 
the glial cells that may be involved in the development of neu-
ropathic pain. This needs to be investigated in future studies in 
order to elucidate the mechanism of development of the PDN 
in STZ-induced diabetic rats.
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